Cardiovascular disease after renal transplantation

被引:61
作者
Dimény, EM [1 ]
机构
[1] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden
关键词
cardiovascular disease; renal transplantation; hyperlipidemia; metabolic risk factors; hyperhomocysteinemia;
D O I
10.1046/j.1523-1755.61.s80.14.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease after renal transplantation. Cardiovascular disease is a major hazard limiting the life expectancy of renal transplant recipients and the most frequent cause of late allograft loss. Patients with renal disease have usually been exposed for both traditional, and for them unique, risk factors over a prolonged period of time and may carry the burden of advanced atherosclerotic disease already at the time of transplantation. The observed survival benefit of transplantation is probably from elimination of the numerous uremia-related risk factors. However. immunosuppressive therapy and the chronic inflammatory state. together with genetic susceptibility and not infrequently impaired renal function, may bring about new potentially atherogenic conditions. Metabolic risk factors may jeopardize both patient and graft survival. Several observational studies provide evidence for the negative impact of preexisting metabolic abnormalities on long-term outcomes. Identification of modifiable cardiovascular risk factors may enable risk reduction also in renal transplant recipients, Results of ongoing intervention trials are awaited. The observed improvement of patient survival after renal transplantation during the past decade may reflect the increasing awareness and more optimal care of patients throughout the course of renal disease.
引用
收藏
页码:S78 / S84
页数:7
相关论文
共 67 条
[21]   Early proteinuria in renal transplant recipients treated with cyclosporin [J].
Fontán, MP ;
Rodríguez-Carmona, A ;
Falcón, TG ;
Valdés, F .
TRANSPLANTATION, 1999, 67 (04) :561-568
[22]  
Hagen W, 2001, KIDNEY INT, V59, pS253, DOI 10.1046/j.1523-1755.2001.07854.x
[23]   Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles [J].
Henry, ML .
CLINICAL TRANSPLANTATION, 1999, 13 (03) :209-220
[24]   Regression of left ventricular hypertrophy by lisinopril after renal transplantation:: Role of ACE gene polymorphism [J].
Hernández, D ;
Lacalzada, J ;
Salido, E ;
Linares, J ;
Barragán, A ;
Lorenzo, V ;
Higueras, L ;
Martín, B ;
Rodríguez, A ;
Laynez, I ;
González-Posada, JM ;
Torres, A .
KIDNEY INTERNATIONAL, 2000, 58 (02) :889-897
[25]   Metabolic cardiovascular syndrome after renal transplantation [J].
Hjelmesæth, J ;
Hartmann, A ;
Midtvedt, K ;
Aakhus, S ;
Stenstrom, J ;
Morkrid, L ;
Egeland, T ;
Tordarson, H ;
Fauchald, P .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (05) :1047-1052
[26]  
Jardine AG, 2000, TRANSPLANTATION, V70, pSS46
[27]  
Jindal RM, 2000, TRANSPLANTATION, V70, pSS58
[28]   FACTORS INFLUENCING WEIGHT-GAIN AFTER RENAL-TRANSPLANTATION [J].
JOHNSON, CP ;
GALLAGHERLEPAK, S ;
ZHU, YR ;
PORTH, C ;
KELBER, S ;
ROZA, AM ;
ADAMS, MB .
TRANSPLANTATION, 1993, 56 (04) :822-827
[29]   Hyperlipidemia in patients with chronic renal disease [J].
Kasiske, BL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S142-S156
[30]   RISK-FACTORS FOR ACCELERATED ATHEROSCLEROSIS IN RENAL-TRANSPLANT RECIPIENTS [J].
KASISKE, BL .
AMERICAN JOURNAL OF MEDICINE, 1988, 84 (06) :985-992